Assessment of the recoverability
of investments in subsidiaries' shares
The net value of investments in subsidiaries
as at 31 December 2020 was PLN 2,848
million, including:
•
investments in shares in Future 1
Sp. z o. o. amounted to PLN 1,103
million,
•
investments in investment
certificates of KGHM VI FIZAN and
KGHM VII FIZAN in the total amount
of PLN 386 million, which portfolio
includes companies operating in
the hotel and health resorts industry,
•
investment in stock and shares of
other entities - PLN 1,359 million.
Investments in subsidiaries are carried at
acquisition cost less impairment losses.
Accounting policies and disclosures
regarding investments in subsidiaries
are included in note 6.1 to the annual
financial statements.
During 2020, the Company carried out
an analysis of the indications of the possible
impairment of investments in all direct and
indirect subsidiaries and estimated
the recoverable amount for:
•
shares in Future 1 Sp. z o. o.,
•
shares in Pol-Miedź Trans Sp. z o.o.,
•
investments in investment
certificates of KGHM VI FIZAN and
KGHM VII FIZAN.
Disclosures regarding impairment tests of
investments in subsidiaries are presented in
part 3 of the financial statements.
The correct determination of the write-down
revaluating shares is an area that requires
significant estimates by the Management
Board. Determining the recoverable amount
for the value of shares in subsidiaries
requires the Management Board to
estimate, among others, expected future
cash flows from investments. Considering
the inherent risk of uncertainty associated
with significant estimates made by the
Management Board, as well as the
significance of items in the financial
statements, we have determined that this is
a key issue for our audit.
Our testing procedures included in particular:
•
verification of compliance of the adopted
valuation principle with applicable accounting
standards,
•
understanding and evaluation of the process
of identification by the Management Board
of indicators for impairment of investments
in subsidiaries,
•
understanding and assessment of
the correctness of applied methods of testing for
impairment in accordance with relevant financial
reporting standards,
•
checking mathematical correctness and
methodological coherence (using internal
valuation experts) of the valuation model
prepared by the Company's Management Board
based on discounted cash flows,
•
assessment of work done by external experts
used by the Company's Management Board,
including their competence and independence,
•
checking mathematical correctness and
methodological coherence (using internal
valuation experts) of valuation reports prepared
by independent external experts,
•
critical assessment of accepted assumptions
and estimates made by the Company's
Management Board to determine
the recoverable amount, including, inter alia:
–
the projection period of future cash flows
based on approved budgets of
companies for which an impairment test
was carried out and the level of
revenues, operating margin and future
investment outlays assumed therein;
–
the applied discount rate (based
on weighted average cost of capital);
and
–
the residual growth rate after forecast
period;
•
assessment of the sensitivity analysis carried
out by the Management Board of the adopted
assumptions for the valuation result,
•
assessment of the correctness and
completeness of disclosures regarding
investments in subsidiaries.